Liquidia Corporation (LQDA) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Net Product Sales: $51.7 million for YUTREPIA in Q3 2025, marking a strong performance in its first full quarter post-launch.

Net Loss: $3.6 million; however, on a non-GAAP basis, Liquidia reported positive adjusted EBITDA of $10.1 million.

Cash Position: $157.5 million at the end of the quarter, with September marking the first month of positive net cash flow, adding $5 million in net cash.

Prescription Metrics: Over 2,000 unique prescriptions and 1,500 active patients initiated therapy, with an 85% referral-to-start conversion rate.

2Strategic Updates and Business Highlights

Product Launch: YUTREPIA is gaining traction in the market, with significant uptake among both new and transitioning patients. Approximately 75% of patients are new to prostacyclin therapies.

Market Positioning: Liquidia aims to redefine the standard of care for inhaled treprostinil, focusing on ease of use, tolerability, and patient compliance.

Clinical Development: Plans to initiate niche open-label studies to expand YUTREPIA's clinical utility, including studies in PAH patients transitioning from oral therapies and potential studies in IPF and PPF.

Next-Generation Product: Development of L606, a sustained-release formulation of inhaled treprostinil, is underway with a pivotal study (RESPIRE) expected to start enrollment in H1 2026.

3Forward Guidance and Outlook

Liquidia expects to maintain its positive cash flow trajectory into 2026 while reinvesting in R&D to support long-term growth.

The company is focused on expanding YUTREPIA's market presence and indications, with continued emphasis on building prescriber awareness and patient access.

4Bad News, Challenges, or Points of Concern

Litigation Risks: Ongoing litigation with United Therapeutics raises uncertainties regarding potential outcomes, which could impact market access and product positioning.

Payer Coverage: While contracts have been signed with major payers, the competitive landscape remains challenging, particularly with other companies entering contracts that could affect YUTREPIA's market share.

Market Dynamics: There is potential for seasonality and ordering choppiness as the product continues to establish itself in the market.

5Notable Q&A Insights

Patient Uptake Drivers: The strong uptake of YUTREPIA is attributed to its unique product profile and the ability to transition patients from oral therapies, with PAH being the primary indication.

Payer Dynamics: Approximately 85% of referrals are converting to prescriptions, indicating effective market access strategies. The company is working to ensure patients are not blocked by contracting issues.

Litigation Impact: The management believes that the ongoing litigation is not significantly affecting physician prescribing behavior, as their primary focus remains on patient outcomes.

Future Patient Projections: While management refrained from providing specific patient number forecasts, they highlighted strong brand awareness and high pull-through rates as indicators of continued growth potential. Overall, Liquidia's Q3 2025 results reflect a robust launch of YUTREPIA, with promising financial metrics and strategic initiatives aimed at sustaining growth, despite facing litigation and competitive challenges.